GNA11 and neoplasm: In addition, our studies in syngeneic mouse melanoma models driven by mutant Gna11 support that the darovasertib/FAKi combination does not affect the tumor immune landscape, which raises the possibility of using this combination in patients that progress while on treatment with recently approved immunotherapies.49